Six Medical and Health Companies Raised Over RMB 100 Million Last Week, Nearly Half from MedTech Sector

　　【Pharmaceutical Network Industry DynamicsAccording to statistics, last week (January 13th - 17th), a total of 16 companies in China's medical and health sector received financing. Among them, six companies secured over 100 million yuan in funding: Cornerstone Robotics, Neo Modulus, MEImedical, FineVision, Kunpeng Gene, and Sunshine Anjin. Nearly half of these six companies come from the medical device industry.
 

　　Cornerstone Robotics: Completes Over 500 Million RMB in Series C Financing
 

January 17 news, innovative surgeryRoboticsCornerstone Robotics Completes Over 500 Million RMB in Series C Financing. This round of financing was led by EQT, a large European private equity investment firm, with participation from Qiming Venture Partners, Alpha JWC Ventures, InnoVen Capital, eGarden Ventures, and Meituan Longzhu, among other investment institutions. UBS Group served as the financial advisor for this round of financing.
 

Public information shows that Cornerstone Robotics is one of the innovative surgical robot companies in China, mainly engaged in the development, manufacturing, and sales of high-end surgical robots.
 

The company stated that the proceeds from this round of financing will be used to accelerate commercialization, develop new surgical robot products, conduct clinical trials, and promote global business development and cooperation.
 

　　Neo Modulus: Completes Nearly 300 Million Yuan in Series C Financing
 

On January 14, Neo Modulus announced the completion of a nearly 300 million yuan C-round financing. This round was led by Shenzhen Capital Group, with participation from some existing shareholders and management. WinX Capital served as the exclusive financial advisor for this round. The funds will primarily be used for the commercial promotion of the company’s multiple innovative medical device products, clinical trials, and the implementation of international strategies.
 

It is reported that this company is an innovative enterprise specializing in the research, development, production, and commercialization of regenerative implantable medical devices. The company has become one of the comprehensive solution providers with a full range of products and advanced technology in the field of regenerative medical materials in China.
 

　　MEImedical: Completes Over 100 Million Yuan in Financing
 

January 15th Update: MEImedical recently announced the completion of an over 100-million-yuan financing round, led by Sequoia China and EF Capital, with participation from Industrial Securities Capital and QingSong Capital. The funds will be used for the construction of medical implant-grade ePTFE production lines, innovative product research and development, and the commercial promotion of certified products, helping MEImedical successfully address the bottleneck issue of core raw material ePTFE in the medical device industry.
 

Public information shows that MEImedical is an innovative medical device enterprise integrating R&D, manufacturing, and commercialization. The company focuses on the innovative R&D, production, and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance. It is committed to providing innovative medical device diagnosis and treatment solutions for patients in China and globally who require peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance.
 

　　FineVision: Completes Over 100 Million Yuan in Series A Financing
 

On January 16, FineVision completed an A-round financing of over 100 million yuan. This round of financing was led by Lilly Asia Ventures, followed by Kaitai Venture Capital, with continued additional investments from existing shareholders Nanjing Innovation Investment Group and Dingxin Capital. The funds raised will be used to promote the clinical trials and registration applications for the "Femtosecond Laser Corneal Refractive Surgery Device," accelerating the product's market entry and commercialization process.
 

It is reported that FineVision focuses on the development of high-end ophthalmic surgical equipment, with a comprehensive layout covering femtosecond refractive correction surgical devices and excimer laser surgical devices, striving to become a game-changer in China's femtosecond laser corneal refractive surgery equipment industry.
 

　　Kunpeng Gene: Completes Over 100 Million Yuan in Series B Financing
 

On January 16, Kunpeng Gene completed a B-round financing of over 100 million yuan. This round was led by Taiping Medical Health Fund, with participation from Anhui Kunhua Fund, some existing shareholders, and the founder. The proceeds will be used to accelerate the research and development, market expansion, and promotion of the company's multiple innovative product pipelines, including tuberculosis and drug-resistance diagnostics, invasive fungal diagnostics, and respiratory pathogen diagnostics.
 

Public information shows that Kunpeng Gene is committed to transforming new technologies in the field of life science research into medical research products related to clinical applications, and developing scientific research and molecular diagnostic products with independent intellectual property rights.
 

　　Sunshine Anjin: Completed Over 100 Million Yuan Pre-A Round Financing
 

On January 15, Sunlight Anjin announced the completion of a Pre-A round of financing exceeding 100 million yuan. This round of financing was led by Qiming Venture Partners, with Boying Capital and Tsinghua Holdings Yinxing following up. The funds from this round of financing will be used for the development of the pain treatment R&D pipeline in preclinical and early clinical stages, accelerating the research and development progress of small molecule drugs targeting the sodium ion channel Nav1.8.
 

The company aims to develop novel analgesics, focusing on Nav1.8 and Nav1.7, two sodium ion channels highly associated with pain perception in the body. The Nav1.8 inhibitor currently under development has demonstrated remarkable analgesic effects and safety, with an expected IND initiation in 2025, officially advancing into the clinical trial phase.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.